These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
25. Plasma brain-derived neurotrophic factor (BDNF) and sphingosine-1-phosphat (S1P) are NOT the main mediators of neuroprotection induced by resistance training in persons with multiple sclerosis-A randomized controlled trial. Jørgensen MLK; Kjølhede T; Dalgas U; Hvid LG Mult Scler Relat Disord; 2019 Jun; 31():106-111. PubMed ID: 30965275 [TBL] [Abstract][Full Text] [Related]
26. Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities. Mehrpour M; Akhoundi FH; Delgosha M; Keyvani H; Motamed MR; Sheibani B; Meysamie A Neurologist; 2015 Oct; 20(4):57-60. PubMed ID: 26468869 [TBL] [Abstract][Full Text] [Related]
27. Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis. Ozkul C; Guclu-Gunduz A; Irkec C; Fidan I; Aydin Y; Ozkan T; Yazici G J Neuroimmunol; 2018 Mar; 316():121-129. PubMed ID: 29329698 [TBL] [Abstract][Full Text] [Related]
28. Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis. Signoriello E; Lus G; Polito R; Casertano S; Scudiero O; Coletta M; Monaco ML; Rossi F; Nigro E; Daniele A Eur J Neurol; 2019 Feb; 26(2):348-355. PubMed ID: 30300462 [TBL] [Abstract][Full Text] [Related]
29. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969 [TBL] [Abstract][Full Text] [Related]
30. Serum and cerebrospinal fluid BDNF concentrations are associated with neurological and cognitive improvement in multiple sclerosis: A pilot study. Yalachkov Y; Anschütz V; Maiworm M; Jakob J; Schaller-Paule MA; Schäfer JH; Reiländer A; Friedauer L; Behrens M; Steffen F; Bittner S; Foerch C Mult Scler Relat Disord; 2023 Mar; 71():104567. PubMed ID: 36805176 [TBL] [Abstract][Full Text] [Related]
32. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476 [TBL] [Abstract][Full Text] [Related]
33. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission. Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236 [TBL] [Abstract][Full Text] [Related]
34. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467 [TBL] [Abstract][Full Text] [Related]
36. Serum lactate as a novel potential biomarker in multiple sclerosis. Amorini AM; Nociti V; Petzold A; Gasperini C; Quartuccio E; Lazzarino G; Di Pietro V; Belli A; Signoretti S; Vagnozzi R; Lazzarino G; Tavazzi B Biochim Biophys Acta; 2014 Jul; 1842(7):1137-43. PubMed ID: 24726946 [TBL] [Abstract][Full Text] [Related]
37. Fitness Shifts the Balance of BDNF and IL-6 from Inflammation to Repair among People with Progressive Multiple Sclerosis. Devasahayam AJ; Kelly LP; Williams JB; Moore CS; Ploughman M Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33810574 [TBL] [Abstract][Full Text] [Related]
38. T2 lesions and rate of progression of disability in multiple sclerosis. Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805 [TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623 [TBL] [Abstract][Full Text] [Related]
40. Uric acid: a potential biomarker of multiple sclerosis and of its disability. Moccia M; Lanzillo R; Palladino R; Russo C; Carotenuto A; Massarelli M; Vacca G; Vacchiano V; Nardone A; Triassi M; Morra VB Clin Chem Lab Med; 2015 Apr; 53(5):753-9. PubMed ID: 25241733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]